Brief: Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout In Ongoing Phase 1B/2A IMX-110 Imminent-01 Clinical Trial
17/07/2023 16:03
July 17 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA REPORTS 2ND POSITIVE INTERIM CLINICAL
TRIAL DATA
READOUT IN RELAPSED/REFRACTORY METASTATIC COLORECTAL CANCER IN
ONGOING PHASE 1B/2A IMX-110 IMMINENT-01 CLINICAL TRIAL
* IMMIX BIOPHARMA INC - DOSE ESCALATION PROCEEDING: DOSING
OF 2ND
DOSE COHORT COMPLETE; NO DRUG-RELATED SEVERE ADVERSE EVENTS WERE
OBSERVED
* IMMIX BIOPHARMA INC - CURRENTLY ENROLLING 3RD, NEXT HIGHER
DOSE
COHORT OF IMX-110 + ANTI-PD-1 ANTIBODY TISLELIZUMAB IN ADVANCED
SOLID TUMORS
Source text for Eikon: ID:nGNX3tdmDV
Further company coverage: IMMX.O
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary